Does Rallies show 13F holders for TARS?

Yes. Rallies tracks hedge fund and 13F ownership data for TARS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TARS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TARS. It does not provide personalized investment advice.

TARS (Tarsus Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Tarsus Pharmaceuticals, Inc. Common Stock (TARS) is a publicly traded Healthcare sector company. As of May 21, 2026, TARS trades at $65.62 with a market cap of $2.70B and a P/E ratio of -56.22. TARS moved +5.71% today. Year to date, TARS is -18.76%; over the trailing twelve months it is +44.36%. Its 52-week range spans $31.36 to $85.25. Analyst consensus is strong buy with an average price target of $95.17. Rallies surfaces TARS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TARS stock?

Hedge funds tracked by Rallies that own TARS include Orbimed Advisors. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tarsus Pharmaceuticals, Inc. Common Stock.

TARS Key Metrics

Key financial metrics for TARS
Metric	Value
Price	$65.62
Market Cap	$2.70B
P/E Ratio	-56.22
EPS	$-1.13
Dividend Yield	0.00%
52-Week High	$85.25
52-Week Low	$31.36
Volume	15
Avg Volume	0
Revenue (TTM)	$535.08M
Net Income	$-48.27M
Gross Margin	0.00%

Top Hedge Funds Holding TARS

Orbimed Advisors holds 154.40K shares of TARS, changed -21.98% as of Dec 31, 2025.

Latest TARS News

Tarsus Doses First Participant in 700-Subject Phase 2 Lyme Prevention Trial — Mar 31, 2026
Tarsus Q4 Revenue $151.7M Beats Estimates; Price Targets Raised to $105, $90 — Mar 6, 2026
Tarsus Pharmaceuticals Posts 150% Revenue Surge to $451M, Eyes $2B Peak Xdemvy Sales — Feb 24, 2026
Tarsus Pharmaceuticals’ Q4 revenue rises 128% but EPS misses slightly — Feb 24, 2026
Tarsus Reports 150% Sales Growth to $451.4M, Launches Phase 2 Programs — Feb 23, 2026

Recent TARS Insider Trades

Neervannan Seshadri sold 2.99K (~$199.52K) on Mar 20, 2026.
Whitfield Dianne C. sold 4.17K (~$279.66K) on Mar 19, 2026.
Wahl Bryan sold 4.23K (~$283.48K) on Mar 19, 2026.

TARS Analyst Consensus

8 analysts cover TARS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.17.

Common questions about TARS

Who owns TARS stock?: Hedge funds tracked by Rallies that own TARS include Orbimed Advisors. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tarsus Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for TARS?: Yes. Rallies tracks hedge fund and 13F ownership data for TARS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TARS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TARS. It does not provide personalized investment advice.